A New Antibody Treatment For Breast Cancer

A year of trastuzumab emtansine (T‑DM1) can keep about 98% of women with small, early‑stage HER2‑positive breast cancer alive and cancer‑free at three years, with far less nerve damage and hair loss than standard…